Blood Immunophenotypes of Idiopathic Pulmonary Fibrosis: Relationship with Disease Severity and Progression.
antifibrotic therapy
immunity and inflammation
interstitial lung diseases
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
07 Sep 2023
07 Sep 2023
Historique:
received:
25
07
2023
revised:
29
08
2023
accepted:
30
08
2023
medline:
4
10
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
(1) The role of the immune response in the pathogenesis of idiopathic pulmonary fibrosis (IPF) remains controversial. We hypothesized that peripheral blood immune phenotypes will be different in IPF patients and may relate to the disease severity and progression. (2) Whole blood flow cytometry staining was performed at diagnosis in 32 IPF patients, and in 32 age- and smoking-matched healthy controls. Thirty-one IPF patients were followed up for one year and categorized as stable or progressors based on lung function, deterioration and/or death. At 18-60 months, immunophenotypes were characterized again. (3) The main results showed that: (1) compared to matched controls, at diagnosis, patients with IPF showed more neutrophils, CD8
Identifiants
pubmed: 37762135
pii: ijms241813832
doi: 10.3390/ijms241813832
pmc: PMC10531459
pii:
doi:
Substances chimiques
CD28 Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto de Salud Carlos III
ID : FIS19/01152
Organisme : Instituto de Salud Carlos III
ID : PI21/00735
Références
Cancer. 2001 Jun 1;91(11):1957-63
pubmed: 11391573
Immunology. 2015 Oct;146(2):185-93
pubmed: 26190355
Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):655-9
pubmed: 8118632
Sci Transl Med. 2013 Oct 2;5(205):205ra136
pubmed: 24089408
J Leukoc Biol. 2015 Aug;98(2):143-52
pubmed: 25743626
J Transl Med. 2021 Dec 7;19(1):496
pubmed: 34876129
Cytokine. 2014 Apr;66(2):119-26
pubmed: 24418172
Expert Rev Respir Med. 2010 Dec;4(6):759-71
pubmed: 21128751
Chest. 1987 Jul;92(1):7-8
pubmed: 3595251
PLoS One. 2010 Jan 29;5(1):e8959
pubmed: 20126467
Lancet. 2011 May 21;377(9779):1760-9
pubmed: 21571362
Int J Mol Sci. 2021 Jun 29;22(13):
pubmed: 34209809
BMJ Open Respir Res. 2022 Jun;9(1):
pubmed: 35715193
PLoS Pathog. 2017 Nov 2;13(11):e1006624
pubmed: 29095912
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Respir Med. 2019 Feb;147:79-91
pubmed: 30704705
Immunity. 2008 Dec 19;29(6):848-62
pubmed: 19100699
PLoS Pathog. 2014 May 15;10(5):e1004078
pubmed: 24831517
Am J Respir Crit Care Med. 2012 Aug 15;186(4):306-13
pubmed: 22582162
Am J Respir Crit Care Med. 2014 Apr 15;189(8):966-74
pubmed: 24628285
Am J Physiol Lung Cell Mol Physiol. 2017 Dec 1;313(6):L1164-L1173
pubmed: 28860144
Lancet Respir Med. 2018 Feb;6(2):154-160
pubmed: 29413083
Mucosal Immunol. 2019 Jan;12(1):212-222
pubmed: 30315241
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47
pubmed: 35486072
Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):1026-32
pubmed: 2327636
Clin Immunol Immunopathol. 1978 Nov;11(3):339-45
pubmed: 309375
Cells. 2021 Oct 15;10(10):
pubmed: 34685744
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
N Engl J Med. 2012 May 24;366(21):1968-77
pubmed: 22607134
Pharmacol Ther. 2021 Jun;222:107798
pubmed: 33359599
Chest. 1987 Jul;92(1):51-6
pubmed: 3595249
Mucosal Immunol. 2013 Nov;6(6):1054-67
pubmed: 24104457
Front Immunol. 2021 Mar 09;12:637974
pubmed: 33767708
Lancet. 2012 Aug 18;380(9842):680-8
pubmed: 22901889
Bull Eur Physiopathol Respir. 1986 May-Jun;22(3):217-24
pubmed: 3730638
Ann Intern Med. 2001 Jan 16;134(2):136-51
pubmed: 11177318
BMJ Open Respir Res. 2021 Nov;8(1):
pubmed: 34794958